-
Potential Gene Therapy for Parkinson’s Linked to GBA Mutations to Enter Clinical Trial
Prevail Therapeutics’ plans to soon open a Phase 1/2 trial of PR001, a potential one-time gene therapy for Parkinson’s patients with GBA1 gene mutations. Read more about the trial here.
What do you think about this news?
Sorry, there were no replies found.
Log in to reply.